Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, TerThera will supply Radiopharm with Terbium-161 and Tb-161 isotope will be linked to a proprietary mAb to form RAD 402, a radiotherapeutic that is being developed by Radiopharm to target KLK3 expression in patients with advanced prostate cancer.
Lead Product(s): RAD 402,Terbium-161
Therapeutic Area: Oncology Product Name: RAD 402
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Radiopharm Theranostics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 24, 2023
Details:
The agreement aims to supply Tb-161 for RAD 602, a radiotherapeutic that is being developed by Radiopharm to target protein tyrosine phosphatase mu (PTPmu or PTPμ) for treatment of brain cancers.
Lead Product(s): RAD602
Therapeutic Area: Oncology Product Name: RAD602
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Radiopharm Theranostics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 17, 2023